The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings,...


Japanese pharma giant Eisai announced its South Korean subsidiary received approval for the kinase inhibitor LENVIMA as a single agent for the first-line treatment of patients with unresectable hepatocellular carcinoma. "LENVIMA is the first new treatment option approved in ten years as a first-line systemic treatment for HCC in South Korea," Eisai said.



from Biotech News